TROP2 exhibits frequent overexpression across major histological subtypes of lung cancer, with particularly high prevalence observed in squamous cell carcinoma (approximately 60%), and adenocarcinoma (42%-64%) (5, 6). Here, TACSTD2 is linked to lung cancer.